Answers are grounded in this paper and cite their sources.
An effective prescribing pathway for liraglutide 3 mg, an approved obesity pharmacotherapy, may improve treatment access. This trial compared a targeted prescribing pathway for liraglutide 3 mg with multiple stopping rules in specialist weight management services (SWMS) to standard SWMS care.
No takes yet. Share an insight, caveat, or question.
Papamargaritis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: